Polycythemia Market Growth Is Accelerating As Industry Transformation Continues
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Polycythemia Market Growth Potential: How Will Market Size Change Through 2030?
The polycythemia market has experienced robust expansion in its size over recent years. It is projected to further expand from $4.68 billion in 2025 to $4.99 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.7%. The historical growth can be ascribed to factors such as the rising prevalence of myeloproliferative disorders, increasing awareness of rare blood diseases, the expansion of specialty hematology centers, higher diagnostic testing rates, and the growing use of cytoreductive drugs.
The polycythemia market size is set for significant expansion in the upcoming years, projected to reach $6.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This future growth is primarily driven by advancements in targeted JAK2 therapies, the increasing adoption of genetic screening, a growing demand for personalized treatment plans, expanding access to specialty biologics, and an enlarging elderly population base. Key trends during this period are anticipated to include the rising uptake of janus kinase inhibitors, increased utilization of interferon based injectable therapies, a growing preference for therapeutic phlebotomy procedures, the expansion of hematocrit monitoring diagnostics, and a shift towards combination drug therapy approaches.
Download A Free Sample Report For Comprehensive Market Insights:
Polycythemia Market Expansion Supported By Key Demand Factors
The increasing occurrence of myeloproliferative diseases is anticipated to boost the polycythemia market in the future. Myeloproliferative diseases are a category of uncommon blood disorders marked by an excessive production of blood cells within the bone marrow, leading to impaired blood function and circulation. The growing prevalence of age-related hematological abnormalities is a key factor behind the increase in these disorders, given that aging populations are more susceptible to bone marrow dysfunction. Polycythemia, as a significant subtype of myeloproliferative diseases involving the overproduction of red blood cells, is instrumental in enhancing clinical awareness, diagnosis, and ongoing management of these conditions, thus supporting market expansion. For instance, in September 2024, Blood Cancer United, a US-based nonprofit organization dedicated to curing blood cancers, reported that over 120,000 people in the United States were estimated to be living with or in remission from myeloproliferative neoplasms (MPNs) in 2023, underscoring the increased prevalence of these chronic hematologic disorders. Consequently, the rising incidence of myeloproliferative diseases is driving the growth of the polycythemia market.
Polycythemia Market Segment Breakdown: Which Categories Generate The Most Revenue?
The polycythemia market covered in this report is segmented –
1) By Type: Primary polycythemia; Secondary polycythemia; Pseudopolycythemia
2) By Drug Class: Antimetabolites; Janus Kinase 2 Inhibitors; Myelosuppressive Agents; Selective Serotonin Reuptake Inhibitors; Folic Acid; Other Drug Classes
3) By Route Of Administration: Oral; Intravenous; Intramuscular
4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Primary Polycythemia: Polycythemia Vera; Familial Primary Polycythemia
2) By Secondary Polycythemia: Hypoxia Induced Polycythemia; Tumor Associated Polycythemia; Drug Induced Polycythemia; Hormone Induced Polycythemia
3) By Pseudopolycythemia: Stress Related Polycythemia; Dehydration Related Polycythemia; Plasma Volume Contraction Related Polycythemia
Polycythemia Market Growth Trends Influencing Competitive Dynamics
Key players within the polycythemia market are concentrating on advanced innovations, such as rusfertide, identified as a pioneering hepcidin mimetic peptide. This substance considerably decreases the requirement for frequent phlebotomy while simultaneously improving the regulation of hematocrit and enhancing patients’ overall quality of life. A hepcidin mimetic is defined as a pharmaceutical agent or compound engineered to mimic the action of hepcidin, which is the body’s principal hormone controlling iron balance. For example, in March 2025, Takeda Pharmaceutical Company Limited, a biopharmaceutical firm headquartered in Japan, announced encouraging preliminary data from its Phase 3 VERIFY study of rusfertide in patients diagnosed with polycythemia vera, showcasing a notable reduction in dependence on phlebotomy, superior hematocrit control, and significant patient-reported improvements, all while maintaining an acceptable safety profile.
Polycythemia Market Key Players And Strategic Industry Positioning
Major companies operating in the polycythemia market are Bristol Myers Squibb Company, Roche Holding AG, Merck And Company Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Incyte Corporation, Ionis Pharmaceuticals Inc., CTI BioPharma Corp., AOP Orphan Pharmaceuticals AG, Silence Therapeutics Plc, Italfarmaco S.p.A., PharmaEssentia Corporation, Karyopharm Therapeutics Inc., Protagonist Therapeutics Inc., Kartos Therapeutics Inc., Geron Corporation, and Perseus Proteomics Inc.
Access The Complete Polycythemia Market Report:
Polycythemia Market Regional Analysis And Leading Geography
North America was the largest region in the polycythemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polycythemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
